alexa Glutamate Transporter 1: Potential Target For The Treatment Of Alcohol Dependence
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Addiction Research & Therapy
August 04-06, 2014 Hilton-Chicago/Northbrook, Chicago, USA

Youssef Sari
Plenary Session: J Addict Res Ther
DOI: 10.4172/2155-6105.S1.015
E vidence indicates that many aspects of alcohol and drug dependence involve alterations in glutamate transmission in central reward brain regions. Studies have demonstrated that drugs of abuse, including alcohol and cocaine, alter glutamate transport. Extracellular glutamate is regulated by a number of glutamate transporters in various brain regions. Of these transporters, glutamate transporter (GLT1) is a key player in the removal of most of the extracellular glutamate. In this presentation the author will discuss the uses of compounds that activate and upregulate GLT1 levels and consequently reduced alcohol consumption in alcohol-preferring (P) rats. It was recently found that ceftriaxone, an FDA-approved drug known to elevate GLT1 expression, attenuates cue-induced cocaine relapse. Also it was found that P rats treated with ceftriaxone showed a significant dose-dependent reduction in alcohol consumption and also the drug attenuated relapse-like alcohol-drinking behavior. In addition, the author will present findings related to a new compound GPI-10 , which is neuroimmunophilin derivative that has therapeutic effect in reducing alcohol intake in P rats. This presentation will provide information about the potential therapeutic role of GLT1 for the treatment of alcohol abuse and dependence
Youssef Sari is an Assistant Professor of Pharmacology. He received his Doctorate in Neuroscience from Pierre and Marie Curie University, Institute of Neuroscience (Paris, France) and subsequently held Postdoc and faculty research positions at Indiana University. He is currently holding a faculty position at the level of Assistant Professor of Pharmacology at the University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Toledo, Ohio, USA. He is the PI of R01 grant project from NIH-NIAA; the project focuses on the role of glutamate transporter 1 (GLT1) in alcohol-drinking behavior using compounds that upregulate this transporter. He has patents for two compounds that may have potential uses for the treatment of alcohol dependence. He is also testing compounds for the treatment of diseases involving oxidative stress.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version